Last reviewed · How we verify
Isoflurane Inhalant Product
Isoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory neurotransmission and suppressing excitatory pathways, producing unconsciousness and analgesia.
Isoflurane is a volatile anesthetic that depresses the central nervous system by enhancing inhibitory neurotransmission and suppressing excitatory pathways, producing unconsciousness and analgesia. Used for General anesthesia for surgical procedures, Maintenance of anesthesia during surgery.
At a glance
| Generic name | Isoflurane Inhalant Product |
|---|---|
| Sponsor | Sunnybrook Health Sciences Centre |
| Drug class | Volatile inhalational anesthetic |
| Target | GABA-A receptor, NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Isoflurane acts primarily through potentiation of GABA-A receptors and inhibition of NMDA receptors, leading to widespread CNS depression. It also modulates other ion channels and neurotransmitter systems. The drug is administered via inhalation and rapidly crosses the blood-brain barrier to produce dose-dependent anesthesia, with quick onset and offset due to its volatile nature and low blood-gas solubility.
Approved indications
- General anesthesia for surgical procedures
- Maintenance of anesthesia during surgery
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Postoperative nausea and vomiting
- Malignant hyperthermia (rare)
Key clinical trials
- SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival (PHASE3)
- Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volatile AnEsthestic Agents (PHASE3)
- Continuous Versus Single-Shot Spinal Anesthesia for Orthopedic Surgery (NA)
- Inhalational Anesthesia vs TIVA in Endoscopic Tympanoplasty (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isoflurane Inhalant Product CI brief — competitive landscape report
- Isoflurane Inhalant Product updates RSS · CI watch RSS
- Sunnybrook Health Sciences Centre portfolio CI